Isoform-resolved 14-3-3/YWHA networks in colorectal cancer: phospho-adaptor mechanisms, biomarker contexts and therapeutic opportunities.

YWHA/14-3-3 proteins are conserved phosphoserine/phosphothreonine-binding adaptors that coordinate signaling-complex assembly, subcellular localization, stress responses and cell-state transitions. Although often discussed as a single adaptor family, colorectal cancer (CRC) studies suggest that individual YWHA isoforms act through distinct clients, RNA-associated layers and tumor-state contexts. In this narrative and mechanistic review, we synthesized PubMed-indexed CRC literature through 18 May 2026 and appraised CRC-relevant mechanistic modules using an explicit evidence-maturity rubric developed by the authors distinct from formal GRADE assessment. We propose an isoform-client-context framework for interpreting 14-3-3 biology in CRC. YWHAG has been linked to CTTN-dependent Wnt/β-catenin activation, whereas YWHAE/14-3-3ϵ protein has been associated with extracellular-vesicle secretion and EV-associated β-catenin/Wnt outputs. Separately, the YWHAE-encoded lncRNA, hereafter referred to as YWHAE lncRNA, has been proposed to activate KRAS/ERK and PI3K/AKT signaling through a competing endogenous RNA mechanism. YWHAZ participates in epithelial-mesenchymal and G2/M transitions through miR-1-3p- and TRIP13-associated mechanisms. YWHAB supports PIK3R2-dependent PI3K/AKT signaling, whereas YWHAH connects NAT10/ac4C regulation, CD8+ T-cell exhaustion and MAPK/ERK-dependent autophagy-associated invasion. SFN illustrates context-dependent tumor-suppressive or stress-adaptive functions. Overall, total 14-3-3 abundance is insufficient for mechanistic or translational interpretation. Interactomics, phosphoproteomics, spatial profiling, extracellular-vesicle analysis and patient-derived models should be used to prioritize YWHA-dependent candidate mechanisms for functional validation. These modules should currently be regarded as testable biomarker and therapeutic hypotheses, not as clinically validated CRC biomarkers or targets.